Organization
New York University School of Medicine
17 abstracts
Abstract
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).Org: New York University School of Medicine, The Ohio State University Comprehensive Cancer Center, Duke University Medical Center, Northwestern University, University of Colorado Comprehensive Cancer Center,
Abstract
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,
Abstract
Decentralized trial recruitment methods to facilitate broad coverage across urban and rural counties for a blood-based test in early colorectal cancer detection.Org: Science 37, Culver City, Freenome Holdings Inc., South San Francisco, New York University School of Medicine,
Abstract
Association of combination tumor texture and vessel tortuosity with progression free survival across PD-L1 subgroups in durvalumab treated non-small cell lung cancer (NSCLC): Blinded validation results from CP1108.Org: Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Emory University Hospital, University Hospitals Cleveland Medical Center, New York University School of Medicine, Laura and Isaac Perlmutter Cancer Center,
Abstract
A targeted panel of actionable high-risk hereditary cancer predisposition genes to identify patients with pathogenic/likely pathogenic variants (PVs) irrespective of meeting established NCCN testing criteria.Org: NYU Langone Medical Center, Natera, Inc., New York University School of Medicine,
Abstract
Fostering diversity and inclusion in the preempt CRC study through strategic site selection and innovative recruitment tools.Org: New York University School of Medicine, Freenome Holdings Inc., Kaiser Permanente Oakland Medical Center,
Abstract
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238.Org: New York University School of Medicine, Bristol Myers Squibb, Istituto Nazionale Tumori IRCCS Fondazione Pascale, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy,
Abstract
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, University of Chicago Comprehensive Cancer Center, Chicago, IL, University of Michigan Rogel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Lineberger Comprehensive Cancer Center,
Abstract
Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.Org: New York University School of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, University of Texas MD Anderson Cancer Center, NYU Grossman School of Medicine, Department of Population Health,
Abstract
Meta-analyses of factors associated with long-term survival after resection of pancreatic ductal adenocarcinoma.Org: Aga Khan University Hospital, NYU Langone Medical Center, The Aga Khan University, University of Maryland School of Medicine, NYU Langone Health, New York, NY,
Abstract
Association of single-click radiomic classifier with response and prognosis in non-small cell lung cancers (NSCLC) treated with immune checkpoint inhibitors.Org: Picture Health, University Hospitals Cleveland Medical Center, New York University School of Medicine, Laura and Isaac Perlmutter Cancer Center, Emory University, Atlanta, GA, USA,
Abstract
Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.Org: Vanderbilt University School of Medicine, Massachusetts General Hospital, Melanoma Institute Australia, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, Georgetown University Medical Center,
Abstract
Machine learning to predict future PSA in patients with prostate cancer managed with active surveillance.Org: Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge University Hospitals NHS Foundation Trust, Department of Radiology and Biomedical Imaging, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Real-world clinical outcomes in a U.S. Asian population with stage IV NSCLC treated with osimertinib (Osi) stratified by EGFR subtype.Org: NYU Langone Health, New York, NY, NYU Grossman School of Medicine, Department of Population Health, New York Oncology Hematology PC, Nykode Therapeutics, New York University School of Medicine,
Abstract
Distinct genetic and phenotypic characteristics of not otherwise specified (NOS) melanoma.Org: NYU Langone Health, New York, NY, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, New York University School of Medicine, NYU Medical Center-Perlmutter Cancer Center,
Abstract
14–3–3eta positivity is associated with higher rheumatoid arthritis disease activity measured by multi-biomarker disease activity assayOrg: Internal Medicine Residency, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn Rheumatology, New York University School of Medicine, New York, USA,
Abstract
ASSOCIATION BETWEEN USE OF TRADITIONAL CHINESE MEDICINE AND MEDICATION ADHERENCE AMONG CHINESE-AMERICAN RHEUMATOLOGY PATIENTS Org: Hospital for Special Surgery, New York University School of Medicine, Mount Sinai Beth Israel, Memorial Sloan Kettering Cancer Center, New York, United States,